

Abstract 26



# Chelating Agents for Biomolecular Labelling with Long-Lived PET Radionuclide, Manganese-52

Madeleine Iafrate, W. D. Shingleton, J. Fonslet, G. O. Fruhwirth, P. J. Blower

# Properties of Radiomanganese-54, 52, 52m, 51, 51m

Isotope	Emission details	Half-life $t_{1/2}$	Other emissions?	Other considerations?
Manganese-54	$\gamma$ (100%), 0.84 MeV	313 days	No	Not for human use
Manganese-52	$\beta^+$ (30%), 0.24 MeV	5.6 days	$\gamma$ (100%), 0.74, 0.94, 1.43 MeV	Good image quality but high energy gammas <sup>1</sup>
Manganese-52m	$\beta^+$ (97%), 1.17 MeV	21 min	$\gamma$ (100%), 1.43 MeV	Generator production but poor image quality, high E gamma
Manganese-51	$\beta^+$ (97%), 0.06 MeV	46 min	$\gamma$ (1%); <sup>51</sup> Cr $\gamma$ (10%), 0.03 MeV <sup>2</sup>	Dosimetry from radioactive daughter <sup>51</sup> Cr $\gamma$ $t_{1/2}$ = 28 days <sup>3</sup>

- Radioisotopes with long physical half-lives are matched for use with processes that have long biological half-lives
- Long-lived isotopes have applications in processes with long biological time frames – for example, cell tracking, antibody labelling

	2.13 MeV		1.09 MeV	gammas
--	----------	--	----------	--------

1. Wooten, A. *et al*, *Appl Radiat Isotopes*, 2015, **96**, 154
2. Graves, SA., *et al*, *Sci Rep*, 2017, **7**, 3033
3. Chu, SYF., *et al*, *The Lund/LNBL Nuclear Data Search*, 1999, accessed 20/03/19.

# Properties of Radiomanganese-54, 52, 52m, 51, 51m

Isotope	Emission details	Half-life $t_{1/2}$	Other emissions?	Other considerations?
Manganese-54	$\gamma$ (100%), 0.84 MeV	313 days	No	Not for human use
Manganese-52	$\beta^+$ (30%), 0.24 MeV	5.6 days	$\gamma$ (100%), 0.74, 0.94, 1.43 MeV	Good image quality but high energy gammas <sup>1</sup>
Manganese-52m	$\beta^+$ (97%), 1.17 MeV	21 min	$\gamma$ (100%), 1.43 MeV	Generator production but poor image quality, high E gamma
Manganese-51	$\beta^+$ (97%), 0.96 MeV	46 min	$\gamma$ (1%); $^{51}\text{Cr}$ $\gamma$ (10%), 0.32 MeV. <sup>2</sup>	Dosimetry from radioactive daughter $^{51}\text{Cr}$ $\gamma$ , $t_{1/2} = 28$ days. <sup>3</sup>
Copper-64	$\beta^+$ (18%), 0.28 MeV	12.7 hrs	$\gamma$ (43%), 1.35 MeV	
Zirconium-89	$\beta^+$ (23%), 0.40 MeV	3.3 days	$\gamma$ (99%), 0.91 MeV	
Iodine-124	$\beta^+$ (23%), 2.13 MeV	4.2 days	$\gamma$ (85%), 0.60, 0.72, 1.69 MeV	Poor image quality, high energy gammas

1. Wooten, A. *et al*, *Appl Radiat Isotopes*, 2015, **96**, 154


2. Graves, SA., *et al*, *Sci Rep*, 2017, **7**, 3033

3. Chu, SYF., *et al*, *The Lund/LNBL Nuclear Data Search*, 1999, accessed 20/03/19.

# Cell Tracking

- Cell therapies ideally **need to be tracked for as long as possible**.
  - Location
  - Survival
  - Safety/Efficacy

## Direct Cell Tracking




All images © Madeleine Iafrate, 2019

# Cell Tracking

- Cell therapies ideally **need to be tracked for as long as possible**.


- Location
- Survival
- Safety/Efficacy

- The physical properties of manganese-52 are ideally suited to direct cell tracking:



- All need a **suitable chelator to stop the radiometal going free!**

## Direct Cell Tracking



All images © Madeleine Iafrate, 2019

- Gawne, PG., *et al*, *Dalton Trans.*, 2018, **47**(28), 9283
- Graves SA., *et al*, *Bioconj. Chem.*, 2015 **26**(10), 2008
- Bansal A., *et al*, *EJNMMI Res.*, 2015, **51**(1), 19



# Chemistry of Manganese







- Manganese can exist in a range of different oxidation states, as can its second and third row transition metal congeners, technetium and rhenium.

1 H		<div>Manganese</div> <div>Avoid confusion.</div> <div>In place of your own name, write</div> <div>"NOT magnesium."</div>																2 He																	
3 Li		4 Be																		5 B		6 C		7 N		8 O		9 F		10 Ne					
11 Na		12 Mg																		13 Al		14 Si		15 P		16 S		17 Cl		18 Ar					
19 K		20 Ca		21 Sc		22 Ti		23 V		24 Cr		25 Mn		26 Fe		27 Co		28 Ni		29 Cu		30 Zn		31 Ga		32 Ge		33 As		34 Se		35 Br		36 Kr	
37 Rb		38 Sr		39 Y		40 Zr		41 Nb		42 Mo		43 Tc		44 Ru		45 Rh		46 Pd		47 Ag		48 Cd		49 In		50 Sn		51 Sb		52 Te		53 I		54 Xe	
55 Cs		56 Ba		57 La		72 Hf		73 Ta		74 W		75 Re		76 Os		77 Ir		78 Pt		79 Au		80 Hg		81 Tl		82 Pb		83 Bi		84 Po		85 At		86 Rn	
87 Fr		88 Ra		89 Ac		104 Rf		105 Db		106 Sg		107 Bh		108 Hs		109 Mt		110 Ds		111 Rg		112 Cn		113 Nh		114 Fl		115 Mc		116 Lv		117 Ts		118 Og	
119 Uue																																			
				58 Ce		59 Pr		60 Nd		61 Pm		62 Sm		63 Eu		64 Gd		65 Tb		66 Dy		67 Ho		68 Er		69 Tm		70 Yb		71 Lu					
				90 Th		91 Pa		92 U		93 Np		94 Pu		95 Am		96 Cm		97 Bk		98 Cf		99 Es		100 Fm		101 Md		102 No		103 Lr					

1. Soon Lee, M., *Elemental Haiku*, <http://vis.sciencemag.org/chemhaiku/> accessed 19/03/19

# Chemistry of Manganese


- Manganese can exist in a range of different oxidation states, as can its second and third row transition metal congeners, technetium and rhenium.
- Chemical comparisons can be drawn between the three metals, which have similar chemistry (due to their periodic relation). However, **manganese is extremely stable in the +2 oxidation state.**
- Commercially available chelators:




Goal: perform a preliminary survey to determine which if any of these chelators would be optimal for  $^{52}\text{Mn}$  biomolecule labelling

# Experimental

**AIM: Fast, efficient labelling at low concentration under mild conditions.**




**Scheme 1.** The antibody was conjugated with the bifunctional chelators and the conjugates were incubated with  $^{52}\text{Mn}$  at a range of concentrations to compare the labelling efficiency of the chelators.



- Several trastuzumab immunoconjugates of bifunctional chelators (DOTA, oxo-DOTA, NOTA, PCTA, DTPA, CDTA, see below panel) were incubated at room temperature with  $^{52}\text{MnCl}_2$  at a range of antibody concentrations at pH 5 and 7.<sup>2</sup>
- Reactions were quenched after 45 minutes with EDTA (50 mM, 2  $\mu\text{L}$ ). Labelling efficiencies from each dilution assay were analysed by iTLC.




## Labelling Efficiency: Overview




Reaction time: 40 minutes,  $\rightarrow$  EDTA quench  
pH 5 =  $\text{NH}_4\text{OAc}$  / pH 7 = PBS  
n = 2, errors =  $\sigma$


# Macrocyclic Chelators for Mn(II)




- Of the commercially available macrocyclic chelators tested, oxo-DOTA and NOTA were efficient chelators of Mn(II) at pH 7, and PCTA at pH 5.




**DOTA**



**Oxo-DOTA**




**NOTA**





**PCTA**

# Macrocyclic Chelators for Mn(II)



- Of the commercially available macrocyclic chelators tested, oxo-DOTA and NOTA were efficient chelators of Mn(II) at pH 7, and PCTA at pH 5.
- Additionally at even lower concentrations, it is clear that there is a significant result regarding the labelling efficiency of **oxo-DOTA**.



# Conclusions

---



- **Manganese-52 direct cell tracking agents** could monitor cells *in vivo* noninvasively by PET for longer than we've ever been able to before.
- **Macrocyclic chelators** are shown to chelate  $^{52}\text{Mn}(\text{II})$  at radiopharmaceutically relevant concentrations.
- **Oxo-DOTA** has emerged as a lead compound for future radiopharmaceutical development due to ease of labelling, without the need of heating.
- **pH** changes inside a cell could make a significant difference to the stability of complexes formed:
  - Further studies needed to ascertain whether this is thermodynamic or kinetic instability.
- Future work will investigate **serum stability** of the bifunctional conjugates used.
- This work is transferable to **other manganese isotopes** because they have identical chemical properties.

## Abstract 26

*Thanks: Phil Blower, Gilbert Fruhwirth, Rafa T. M. de Rosales, Bill Shingleton, and Peter Gawne.*


Madeleine Iafrate, W. D. Shingleton, J. Fonslet, G. O. Fruhwirth, P. J. Blower

# Production of Manganese-52, by J. Fonslet (Hevesy Lab) et al.





# Applications of Radiomanganese in Nuclear Medicine



1. Chauncey, D. *et al*, *J Nuc Med*, 1977, **18**(9), 933
2. Urquhart, J. *et al*, *Am J Cardiol*, 1982, **49**(4), 979
3. Topping, GJ. *et al*, *Med Phys*, 2013, **40**(4), 042502
4. Lewis, CM. *et al*, *Theranostics*, 2015, **5**(3), 227
5. Graves SA. *et al*, *Bioconj Chem*, 2015, **26**(10), 2118
6. Wooten, A. *et al*, *Appl Radiat Isotopes*, 2015, **96**, 154

7. Brunnquell, CL. *et al*, *Contrast Media Mol Imaging*, 2016, **11**(5), 371
8. Wooten, A. *et al*, *PLoS One*, 2017, **12**(3), e0174351
9. Hernandez, R. *et al*, *Diabetes*, 2017, **66**(8), 2163
10. Graves, SA. *et al*, *Sci Rep*, 2017, **7**(1), 3033
11. Gawne, PG. *et al*, *Dalton Trans*, 2018, **47**(28), 9283
12. Brandt, MR. *et al*, *Dalton Trans*, 2019, **48**, 3003